These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18559583)

  • 1. Phase 0 trials: an industry perspective.
    Eliopoulos H; Giranda V; Carr R; Tiehen R; Leahy T; Gordon G
    Clin Cancer Res; 2008 Jun; 14(12):3683-8. PubMed ID: 18559583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy.
    Guillot C; Hall J; Herceg Z; Merle P; Chemin I
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):137-42. PubMed ID: 23953496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
    Gartner EM; Burger AM; Lorusso PM
    Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase.
    Li X; Delzer J; Voorman R; de Morais SM; Lao Y
    Drug Metab Dispos; 2011 Jul; 39(7):1161-9. PubMed ID: 21436403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.
    Gangloff AR; Brown J; de Jong R; Dougan DR; Grimshaw CE; Hixon M; Jennings A; Kamran R; Kiryanov A; O'Connell S; Taylor E; Vu P
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4501-5. PubMed ID: 23850199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
    Ferraris DV
    J Med Chem; 2010 Jun; 53(12):4561-84. PubMed ID: 20364863
    [No Abstract]   [Full Text] [Related]  

  • 15. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
    Bryant HE; Helleday T
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based drug development: a rational approach to efficiently accelerate drug development.
    Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
    Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.